Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
1/2/25 | Neumora Therapeutics (NMRA) | Navacaprant for Major Depressive Disorder (MDD) | Subscribers Only | Subscribers Only | Subscribers Only |
12/20/24 | Lexicon Pharmaceuticals (LXRX) | Inpefa for Diabetes Mellitus, Type I | Subscribers Only | Subscribers Only | Subscribers Only |
12/20/24 | GSK (GSK) | Zejula for Ovarian Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
12/20/24 | GSK (GSK) | Jemperli for Ovarian Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
12/20/24 | Novo Nordisk (NVO) | CagriSema for Obesity | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
03/25/2024 | Subscribers Only | Subscribers Only | Regulatory - Response to Complete Response Letter |
06/30/2024 | Subscribers Only | Subscribers Only | Trial Announcement - Trial Completion (Emerging Markets) |
09/12/2024 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
09/30/2024 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
10/16/2024 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |